The property developer has backed Chinese Academy of Medical Sciences spinout Juventas to help advance its clinical-stage oncology cell therapy candidates.
Juventas, a China-based immunotherapy developer based on research at Chinese Academy of Medical Sciences, raised $65m in funding on Wednesday.
The company did not identify investors, however, DealStreetAsia reported it was led by private equity fund CMG-SDIC Capital and backed by commercial property developer Parkland Group.
The round also included Kaixin Biotechnology – possibly part of automotive retailer Kaixin Auto – Tzitzit Asset, Tianjin Venture Capital, Ruisheng Investment, Xiangrong Capital, Dalton Venture and Jiadao Fanghua Investment.
Parkland took part through its Daxie Pengchuang Investment vehicle. DealStreetAsia reported the round size as RMB450m, which would equate to $68.4m.
Juventas is developing cellular immuno-oncology therapies for acute lymphatic leukaemia and haematologic tumours. It recently began a phase 2 registration study for its lead drug candidate, CNCT19 for relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL).
CNCT19 is also in a phase 1 clinical trial…
The company did not identify investors, however, DealStreetAsia reported it was led by private equity fund CMG-SDIC Capital and backed by commercial property developer Parkland Group.
The round also included Kaixin Biotechnology – possibly part of automotive retailer Kaixin Auto – Tzitzit Asset, Tianjin Venture Capital, Ruisheng Investment, Xiangrong Capital, Dalton Venture and Jiadao Fanghua Investment.
Parkland took part through its Daxie Pengchuang Investment vehicle. DealStreetAsia reported the round size as RMB450m, which would equate to $68.4m.
Juventas is developing cellular immuno-oncology therapies for acute lymphatic leukaemia and haematologic tumours. It recently began a phase 2 registration study for its lead drug candidate, CNCT19 for relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL).
CNCT19 is also in a phase 1 clinical trial…
LEADERSHIP SOCIETY
Informing, connecting, and transforming the global corporate venture capital ecosystem.The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
University of Notre Dame tries new, supersized approach to creating spinouts
University of Notre Dame tries new, supersized approach to creating spinouts
A new $35m fund will be managed by external venture studio High Alpha Innovation and will work with the university on creating new startups.
How Basel supercharged its spinout rate
How Basel supercharged its spinout rate
Basel has quietly built a life sciences ecosystem that’s becoming hard to ignore.
Crumbling system, fragile lives: can spinouts help in the senior care crisis?
Crumbling system, fragile lives: can spinouts help in the senior care crisis?
From a chest-worn device to help with Parkinson's symptoms to stress measuring socks — here are the spinouts providing support for senior citizens.
